Zuranolone

Pre-clinicalRecruiting
0 watching 0 views this week๐Ÿ’ค Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depression, Postpartum

Conditions

Depression, Postpartum

Trial Timeline

Jun 30, 2025 โ†’ Aug 24, 2026

About Zuranolone

Zuranolone is a pre-clinical stage product being developed by Biogen for Depression, Postpartum. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07047820. Target conditions include Depression, Postpartum.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT07398469Pre-clinicalRecruiting
NCT07047820Pre-clinicalRecruiting
NCT05655507Phase 1Completed

Competing Products

20 competing products in Depression, Postpartum

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
QuetiapineAstellas PharmaPre-clinical
23
duloxetine + escitalopram + placeboEli LillyPhase 3
77
duloxetineEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
85
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
duloxetine + duloxetineEli LillyPre-clinical
23
olanzapine + ziprasidoneEli LillyApproved
85
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85
Drug treatment with CymbaltaEli LillyApproved
85
DuloxetineEli LillyApproved
85